SPDR S&P Biotech ETF (XBI)

Latest stories mapped to XBI

Everything Newsig has mapped to XBI, newest first — no importance filter. Topic pages list critical and high-importance stories only.

• 2026-10-16 Moderna retreats 8% amid valuation debate ahead of cancer data
• 2026-10-16 IPO market review: biotech leads a quiet week as Anthropic waits in the queue
• 2026-10-16 RNAi drug developer City climbs after upsized IPO
• 2026-10-16 City Therapeutics surges in market debut after upsizing $200M IPO
• 2026-10-16 Erasca drops after sacking COO
• 2026-10-16 Jefferies says this stock remains a top pick among biotech midcaps
• 2026-10-15 Crescent Biopharma advances cancer drug trials across portfolio
• 2026-10-14 Liquidia soars 27% after settlement resolves litigation
• 2026-10-14 Arrowhead spikes after early-stage trial data for Alzheimer’s disease
• 2026-10-14 William Blair resumes Jasper Therapeutics stock with outperform rating
• 2026-10-13 Liquidia stock surges 40% on $380.7M litigation settlement with UTHR
• 2026-10-13 Xenon Pharmaceuticals stock hits 52-week low at 35.04 USD
• 2026-10-13 Pinnacle Food skyrockets after biotech breakthrough
• 2026-10-12 Biomea Fusion to report Phase I trial results Tuesday
• 2026-10-09 JPMorgan initiates C4 Therapeutics stock coverage at Overweight
• 2026-10-08 Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
• 2026-10-07 US government, Google join Zuckerberg-backed Biohub in $1.8 billion push for AI biology data
• 2026-10-06 Why is Arrivent Biopharma stock collapsing today?
• 2026-10-06 ArriVent stock tumbles 60% after trial misses primary endpoint
• 2026-10-05 Genmab stock surges 11% on positive cancer drug trial data